Seattle Genetics, Inc. (OQ:SGEN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 21823 30th Dr SE
BOTHELL WA 98021-3907
Tel: N/A
IR: See website
Key People
Clay B. Siegall
Chairman of the Board, President, Chief Executive Officer
Todd E. Simpson
Chief Financial Officer
Jean I. Liu
Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
Vaughn B. Himes
Chief Technical Officer
Roger D. Dansey
Chief Medical Officer
Business Overview
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.
Financial Overview
For the six months ended 30 June 2020, Seattle Genetics, Inc. revenues increased 24% to $512.5M. Net loss increased from $92.6M to $189.6M. Revenues reflect Net product sales increase of 49% to $439M, Royalty revenues increase of 32% to $51.6M. Higher net loss reflects Selling, general and administrative increase of 52% to $247.9M (expense), Research and development increase of 22% to $393.3M (expense).
Employees: 1,605 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $27,257M as of Jun 30, 2020
Annual revenue (TTM): $1,016M as of Jun 30, 2020
EBITDA (TTM): -$299.32M as of Jun 30, 2020
Net annual income (TTM): -$255.68M as of Jun 30, 2020
Free cash flow (TTM): -$312.41M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 173,996,620 as of Jul 27, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.